Argenx: from profit to nine straight losses.
- Industry
- Biological Products,
- Headquarters
- Netherlands
- Ticker
- ARGX (Nasdaq)
- Sources
- SEC filings (2017–2026), Stratrix's verified Decision Cases, market data and official economic statistics for Netherlands
- Data as of
- November 2, 2026
- From profit to nine straight losses. Argenx lost money every year from 2015 to 2023: $2.3 billion in all. 2024 was its first profit in ten years: $0.8 billion.
- Ahead of almost everyone like it. From 2016 to 2025, its revenue grew 25844% in US dollars; the median among 586 large manufacturers grew 58%. It outgrew 99% of them.
- Still smaller than it was. Revenue reached $0 billion in 2023, 93% below its 2021 peak of $0.5 billion.
Financial results
| Fiscal year | Revenue | Net income | |
|---|---|---|---|
| 2016 | $0 billion | −$0 billion | |
| 2017 | $0 billion | −$0 billion | |
| 2018 | $0 billion | −$0.1 billion | |
| 2019 | $0.1 billion | −$0.2 billion | |
| 2020 | $0 billion | −$0.6 billion | |
| 2021 | $0.5 billion | −$0.4 billion | |
| 2022 | $0 billion | −$0.7 billion | |
| 2023 | $0 billion | −$0.3 billion |
As reported in its annual filings. Losses in red.
Has Argenx had layoffs?
Headcount, as reported
| Annual report | Employees | As of |
|---|---|---|
| 20-F for 2023 | 1,148 | December 31, 2023 |
| 20-F for 2024 | 1,599 | December 31, 2024 |
| 20-F for 2025 | 1,863 | December 31, 2025 |
Job cuts, severance and restructuring
The filing reports a termination benefit line in personnel expenses for 2023, but describes no layoff, workforce reduction, or restructuring program.
“Termination benefits 1,089 401 818 Share‑based payment 226,830 151,912 167,965 Employer social security contributions stock options 7,987 5,910 5,002 Total personnel expenses $ 529,377 $ 396,750 $ 325,110 The post-employment benefits relate to the pension plans the Company has in place for its employees.” 20-F for 2023
Argenx has filed no restructuring notice (Form 8-K, Item 2.05) since 2016. Companies file one only for a cut they judge material, so many announced layoffs never appear as one. This page shows what the company reported to the SEC, not news reports or state layoff notices.
Who are Argenx's competitors?
Who Argenx names
Argenx’s annual reports for 2023 to 2025 describe its competition by kind of business and do not name competing companies.
Who names Argenx
Companies whose own annual reports name Argenx as a competitor.
“GC Biopharma introduced its 10% IVIG product, Alyglo TM , to the U.S. market in 2024 and Argenx obtained FDA approval in 2021 for VYVGART (IV) and in 2024 for VYVGART Hytrulo (subcutaneous), a non-plasma derived product that would treat patients with chronic inflammatory demyelinating polyneuropathy (“CIDP”).” 20-F for 2025
“Additionally, there are a number of Phase 3 compounds (dazukibart (anti-IFN; Pfizer), anifrolumab (Saphnelo®; anti-IFN; AstraZeneca) and efartigimod (Vyvgart®; anti-FcRn; Argenx) which could launch before the end of the decade.” 20-F for 2025
Layoffs, acquisitions, competitors and subsidiaries are read from Argenx’s annual reports (20-F for 2025, 20-F for 2024, 20-F for 2023), as of 2026-03-19.
Everything behind these findings, ready for your board deck.
- Economic context: 6 measures for Netherlands, every year since 2016, from the official sources.
- Peer comparison: against 953 companies of its size in its sector.
- Financial results: ten years of revenue, operating and net income, and every annual report, linked.
- Methods and sources, so each number can be checked and cited.
The full data sheet downloads with the Data Plan. To see exactly what you get first, open the Boeing sample PDF or Excel.
More from Stratrix
The Business Model Wizard
Make the seven choices that define your model, test your numbers against real companies, and meet the rival AI would build against you.
Free · about twelve minutesBuild your Model Thesis →Test a decision, free
Set a live decision against the companies that made it before you.
AcquisitionsThe Distance TestDivestituresThe Divestiture TestDiversificationThe Diversification TestMake or buyThe Make-or-Buy TestWeekly email
Stratonomics, every Tuesday
One data story every Tuesday: what happened, what it means, and the figures you can quote. Free.